InDex Pharmaceuticals Holding AB (publ), a Sweden-based pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options, announced on Friday an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod.
The result of the dose selection is likely to be provided in the fourth quarter of 2023. The company will have finalised the evaluation of consequences on the overall development timeline, including top line results in CONCLUDE, at that point in time.
The CONCLUDE study, a phase III study, is assessing the first-in-class TLR9 agonist cobitolimod as a novel treatment for subjects with moderate to severe left-sided ulcerative colitis. It includes around 440 subjects and is being carried out at various clinics in more than 30 countries in Europe, the Americas and the Asia-Pacific region.
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics